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Introduction
Coronary artery disease (CAD) is one of the main causes of 
morbidity around the world. Although diagnosis and treat-
ments have improved, its prevalence shows a tendency to 
increase.1 A set of environmental and acquired risk factors 
such as hypertension, diabetes, obesity, hyperlipidemia, 
smoking and family history have been accepted as the lead-
ing causes of CAD.2,3 However, some studies on family 
history4 and twin investigations5 have led researchers to 
propose a role for some genetic contributions to CAD. 
Therefore, some genetic factors have been proposed to trig-
ger CAD, especially polymorphisms in genes regulating 
blood coagulation, blood pressure and lipid metabolism.6 
Since an occlusive or nonocclusive thrombus formation is 
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the key point of CAD from an unstable angina to an 
ST-elevated myocardial infarction (MI), fibrinolysis has an 
important role in CAD.7 Crucially, 50%–70% of cases of 
sudden death due to ischemic heart disease are the result of 
primary thrombotic events according to coronary Arteries.8
Plasminogen activator inhibitor-1 (PAI-1) is one of sug-
gested genetic factors predisposing patients to CAD.9 PAI-
1 has an important prothrombotic role and its expression is 
increased in sclerotic plaques. Also, high levels of this pro-
tein are detectable in the serum of post-MI patients.10
One of the known polymorphisms of the PAI-1 gene is 
the 4G/5G single base pair (bp) polymorphism at 675 bp 
upstream from the transcriptional start site in the promoter 
region. This polymorphism and its association to CAD 
were first described by Dawson et al. in 1993.11
Homozygosis for 4G has a 25% increase of PAI-1 in the 
plasma compared to 5G homozygous, while the 4G/5G 
genotype presents an intermediate level.12 There is evi-
dence supporting both effective relationships between 
PAI-1 and CAD,13–15 and a lack of this association16–18 
based on different epidemiologic studies.
Angiotensin-converting enzyme (ACE) is the major 
component of the renin angiotensin system (RAS), which 
some studies indicate is important for CAD development. 
ACE converts angiotensin I to angiotensin II. In 1990, 
Rigat et al. described the insertion/deletion (I/D) polymor-
phism in ACE whose homozygosity in its deletion pro-
duces more ACE in serum and, therefore, more angiotensin 
II, which is a vasopressor and aldosterone-stimulating pep-
tide.19 Additionally, some studies show that angiotensin II 
increases PAI-1 expression based on transcriptional impli-
cation on its messenger RNA (mRNA).20 For the first time, 
in 1992, Cambien et al. showed the association of the D 
allele with CAD.21 Since then, numerous22–27 studies 
attempted to demonstrate this relationship, but it remains 
controversial. In this study we examine the association of 
PAI-1 and ACE polymorphisms as well as their combina-
tion effect on CAD, considering the conventional risk fac-
tors in case and control groups.
Materials and methods
Study population
A total of 153 individuals living in Tehran participated in 
our case-control study comprising 61 patients (45 men, 
mean age 55.3±8.6 years and 16 women, mean age 53.5±9.7 
years) having experienced coronary heart disease from an 
unstable angina to ST elevated MI. These patients under-
went angiography in Shahid Modarres Hospital. Ninety-
two healthy controls who were also recruited for this study 
were referred to the Tehran blood transfusion center for 
voluntary blood donation (74 men, mean age 53.5±9.2 
years and 18 women, mean age 54.4±8.9 years old).
CAD was confirmed in all patients by having coronary 
artery stenosis more than 50%, angiographically. This study 
was approved by the blood transfusion organization and the 
Shahid Modarres Hospital Ethics Committee. All partici-
pants were informed and signed the corresponding consent 
form. Demographic data and medical history such as con-
ventional risk factors for CAD were collected in a question-
naire following a standard procedure of our research group.
Genotyping
Three ml of whole blood were collected from each partici-
pant in k2 ethylenediaminetetraacetic acid (EDTA). The 
DNA was isolated from leukocytes based on the selective 
detergent-mediated DNA precipitation from crude lysate 
according to the manufacturer’s instructions (Thermo 
Scientific). DNA concentration was measured at 260 nm 
and quality controls were performed.
PAI-1 and ACE genotypes were determined by poly-
merase chain reaction (PCR) using the amplification 
refractory mutation system (ARMS) technique. For ACE 
I/D polymorphism, as described,28 a sense 5’GAC 
CTGCTGCCTATAGACT3’ and anti-sense 5’GGGTAA 
AACTGGAGGATGGGT3’ primers that formed a 233 bp 
band for D and 521 bp band for I were used, respectively. 
If a sample was heterozygote both for 233 bp and 521 bp, 
bands should be detected. To avoiding mistyping of the 
DD genotype, another specific primer pair for I was 
applied: sense 5’GATTACAGGCGTGATACAGT3’ and 
antisense 5’GGGTAAAACTGGAGGATGGGT3’.
For the PAI-1 4G/5G polymorphism, as described,29 two 
reactions were performed for each sample: one reaction for 
4G containing its own specific primer and another one for 
5G, respectively. The primers were the following: a sense 
control primer 5’AAGCTTTTACCATGGTAACC 
CCTGGT3’, a 4G allele-specific primer 5’ AGAGTCT 
GGACACGTGGGGA3’, a 5G allele-specific primer 
5’AGAGTCTGGACACGTGGGGG3’ and a common anti-
sense primer 5’ TGCAGCCAGCCACGTGATTGTC 
TAG3’. In both reactions, a 257 bp band was amplified as a 
control that formed by control sense and common anti-
sense primers. In addition, a 136 bp band was observed 
for each 4G and 5G reactions if their alleles were present, 
yielded with allele-specific sense and common anti-sense 
primers. In the 4G/5G heterozygote the 136 bp band was 
amplified in both reactions and in the homozygote it was 
presented in only one reaction tube. All primers were 
synthesized by Bioneer (Korea). For both ACE and PAI-
1, all reactions were performed in 25 μl volume contain-
ing 100 ng DNA, 10 mmol/l Tris-HCl (pH: 8.3), 50 
mmol/l KCl, 1 mmol/l MgCl2, 0.2 mmol/l dNTP, 10 
pmol of each primer (for PAI-1, 5 pmol of each sense 
allele-specific primers and control, and 10 pmol of com-
mon anti-sense primer.), 1 U Taq polymerase (Genet Bio, 
Korea). PCR reactions were carried out in the following 
thermal conditions: initial denaturation at 95°C for five 
minutes, afterwards for ACE it was followed by 35 
cycles including denaturation at 94°C for 35 seconds, 
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annealing at 52°C for one minute and extension at 72°C for 
one minute. For PAI-1 32 cycles were performed, including 
denaturation at 94°C for 35 seconds, annealing at 64.5°C for 
30 seconds and extension at 72°C for 30 seconds followed 
by final extension at 72°C for five minutes for all reactions. 
PCR products were electrophoresed on 2% agarose and 
visualized under ultraviolet (UV) light after staining with 
ethidium bromide as shown in Figures 1 and 2.
Statistical analysis
Genotype distribution and allele frequencies were repre-
sented as absolute numbers and percentages. Comparisons 
between patients and controls were performed by the Chi-
square test. The associations between conventional risk 
factors and genotypes with CAD were reported using odds 
ratio (OR) with 95% confidence interval (CI). To deter-
mine crude OR and adjusted OR for other risk factors, sim-
ple and multiple logistic regressions were applied, 
respectively. To evaluate the interaction between studied 
genotypes, an interaction factor was introduced in the 
logistic regression model. The p value <0.05 was consid-
ered as significant correlation. Genotype distributions 
were compatible with Hardy-Weinberg equilibrium 
assessed by Chi-square test. All analyses were carried out 
using SPSS software for Windows version 20.
Figure 1. PAI-1 4G/5G polymorphism detection in agarose gel. Gel (a) is for 5G and gel (b) is for 4G. Number 1 is a 5G/5G, number 
2 is 4G/4G and number 3 is a 4G/5G sample. The 257 bp band is for control and the 136 bp band is yielded by 4G and 5G allele-
specific primers. PAI-1: plasminogen activator inhibitor-1; bp: base pair.
Figure 2. Gel (a) shows the specimens that have insertion yielded a 521 bp band and those that have deletion yielded a 234 bp 
band. For heterozygotes both 521 and 234 bp bands are presented. Gel (b) shows a 233 bp band is formed from confirmatory 
primers for insertion for the same specimens. bp: base pair.
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Results
A total of 153 individuals participated in our study; a 
greater percentage of patients (73.8%) and controls 
(80.4%) were male, with a mean age of 58.5±10.8 and 
51.5± 6.4 years, respectively. The body mass index (BMI) 
of 29.5% of patients versus 19.6% of controls was ≥30.
As expected, differences between patients and controls 
were significant (p value ≤ 0.001) for conventional CAD 
risk factors such as hypertension (OR = 17.98; 95% CI: 
6.41–50.45), diabetes (OR = 7.52; 95% CI: 2.82–20.09), 
hyperlipidemia (OR = 4.84; 95% CI: 2.03–11.52), smok-
ing (OR = 4.15; 95% CI: 1.83–9.42) and family history 
(OR = 3.48; 95% CI: 1.72–7.05). Sex and BMI did not 
significantly differ between patients and controls. ACE 
and PAI-1 genotypes in patients did not significantly differ 
from controls (p value = not significant) (Table 1). To 
adjust OR for confounding factors, a multiple logistic 
regression was performed. Also other classical risk factors 
apart from sex and BMI contributed to CAD development. 
However, ACE and PAI-1 genotypes were not apparently 
involved in CAD susceptibility (Table 1).
As shown in Table 2, the distribution of different types 
of PAI-1 and ACE genotypes with their allele frequencies 
in case and control groups are shown with respect to the 
PAI-1 genotype; 24.6%, 45.9% and 29.5% of patients 
show the 4G/4G 4G/5G, and 5G/5G genotypes, respec-
tively. The corresponding percentages for healthy blood 
donors were 20.7%, 42.2% and 37.0%. The allele fre-
quency of 4G and 5G was 57% and 62.6% among patients, 
and 43% and 37.4% for controls.
Regarding the ACE genotype; I/I, I/D and D/D in 
patients amounted to 29.5%, 45.9% and 24.6%, respec-
tively; in the control group they were 40.2%, 40.2% and 
Table 1. Patient and control group demographic and genotypic characteristics.
Control Patient Groups Adjusted OR  
(95% CI)
p value
 Unadjusted OR 
(95% CI)
p value
Sex  
 Male 74 (80.4%) 45 (73.8%) 0.68 (0.32–1.48) NS 0.95 (0.25–3.68) NS
 Female 18 (19.6%) 16 (26.2%) 1 1  
Age 51.5±6.4 58.5±10.8 1.11 (1.06–1.16) <0.001 1.12 (1.04–1.20) 0.002
BMI categories  
 BMI < 30 74 (80.4%) 43 (70.5%) 1 1  
 BMI ≥ 30 18 (19.6%) 18 (29.5%) 1.72 (0.81–3.66) NS 1.35 (0.42–4.31) NS
Hyperlipidemiaa  
No 83 (90.2%) 40 (65.6%) 1 1  
Yes 9 (9.8%) 21 (34.4%) 4.84 (2.03–11.52) <0.001 5.58 (1.60–19.51) 0.007
Hypertensionb  
 No 87 (94.6%) 30 (49.2%) 1 1  
 Yes 5 (5.4%) 31 (50.8%) 17.98 (6.41–50.45) <0.001 29.98 (7.41–121.4) <0.001
Diabetesc  
 No 86 (93.5%) 40 (65.6%) 1 1  
 Yes 6 (6.5%) 21 (34.4%) 7.52 (2.82–20.09) <0.001 4.52 (1.18–17.32) 0.03
Smokingd  
 No 81 (88%) 39 (63.9%) 1 1  
 Yes 11 (12%) 22 (36.1%) 4.15 (2.82–20.09) 0.001 9.99 (3.04–32.81) <0.001
Family history  
 No 72 (78.3%) 31 (50.8%) 1 1  
 Yes 20 (21.7%) 30 (49.2%) 3.48 (1.72–7.05) 0.001 3.22 (1.05–9.87) 0.04
PAI  
 5G/5G 34 (37%) 18 (29.5%) 1 1  
 4G/5G–4G/4G 58 (63%) 43 (70.5%) 1.40(0.70–2.80) NS 1.12 (0.35–3.58) NS
ACE  
 D/D–I/D 74 (80.4%) 46 (75.4%) 1 NS 1 NS
 I/I 18 (19.6%) 15 (24.6%) 1.34 (0.62–2.92) 1.44 (0.47–4.38)  
aTotal cholesterol≥200 mg/dl, LDL ≥ 130 mg/dl, HDL≤ 40, Trigyserid ≥ 150 mg/dl or patent uses lipid-lowering drugs. b≥ 140/90 mmHg. cFasting 
blood sugar ≥120 or patient given hypoglycemic or insulin treatment. dEx- or persistent smoker. BMI: body mass index; LDL: low-density lipoprotein; 
HDL: high-density lipoprotein. NS: not significant; CI: confidence interval; OR: odds ratio; PAI: plasminogen activator inhibitor; ACE: angiotensin-
converting enzyme; I: insertion; D: deletion.
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19.6%. Allele frequencies for the ACE gene were 55.7% 
and 64.55% for I and D in patients, and 44.3% and 35.5% 
for controls.
We also performed a study on the co-expression of vari-
ous conditions of ACE and PAI-1 genotype in CAD devel-
opment. The results are shown in Table 3; CAD risk was 
not increased in any condition significantly.
Discussion
In this study, the ACE and PAI genotypes and their combi-
nations did not show a significant correlation with CAD. 
Moreover, there was no significant genotype difference 
between patients and control groups. Therefore, our inves-
tigation supports that conventional and environmental risk 
factors are the principal causes of CAD2,3 by univariate 
and multivariate regression studies. Among conventional 
risk factors, hypertension, hyperlipidemia, diabetes, smok-
ing and family history enhanced the hazard rate for CAD 
through crude and adjusted OR. On the other hand, sex and 
BMI did not have an indicative effect on hazard rate in the 
current study, although the selection of controls was biased 
toward males with standard BMIs. Therefore, our study 
cannot conclude on sex or BMI. Additionally, the number 
of paricipants involved in this study also limits the conclu-
sions in this regard.
ACE I/D polymorphism is one of the genetic factors 
linked to CAD because of its critical role in atherosclerosis 
and also hypertension.30 Since 1992, when the association 
between the DD genotype in ACE and CAD21 was pub-
lished, several researchers reported the prevalence of the 
ACE I/D polymorphism in different populations and eth-
nicities, including the positive effect of the DD polymor-
phism on CAD development.22–24 However, some studies 
did not find an association between the ACE polymor-
phism and CAD susceptibility.25–27 A meta-analysis was 
performed by Agerholm-Larsen and colleagues31 to clarify 
the association of the ACE I/D polymorphism with ACE 
activity in plasma, blood pressure, risk of MI, ischemic 
heart disease and ischemic cerebrovascular disease through 
large and small studies. They selected 46 studies, includ-
ing those investigating 32,715 white individuals. They 
concluded that the I/D polymorphism increases ACE activ-
ity in plasma, but has no effect on blood pressure. In addi-
tion, it was not an independent risk factor for both ischemic 
heart disease and ischemic cerebrovascular disease in large 
studies, in contrast to results from small studies.
Recently, another meta-analysis was carried out32 to 
investigate the involvement of ACE I/D in the develop-
ment of coronary heart disease in the Chinese population. 
The researchers surveyed 46 studies consisting of 5215 
cases and 4782 controls. They showed a significant asso-
ciation between the DD genotype and vulnerability to cor-
onary heart diseases in the Chinese population.
Something similar is observed for the PAI-1 gene. The 
PAI-1 4G/5G polymorphism in its promoter regulates the 
amount of this protein in cells. 4G/4G carriers produce 
more PAI-1 and possess less capacity for fibrinolysis.11 
Thus, it is thought that the PAI-1 4G/5G polymorphism is 
another genetic factor leading to thrombotic events in deep 
veins and coronary arteries; the association of the PAI-1 
4G/5G polymorphism and MI11 has been previously 
described. However, this association is still controversial 
owing to contradictory experimental results published by 
different groups. The studies carried out by Eriksson,12 
Song,13 Abboud14 and Margaglione15 support the correla-
tion of the PAI-1 4G/4G genotype with CAD development 
in contrast to the studies by Ye S,16 Anderson17 and 
Crainich.18 Overall, in 2012 Gong33 and colleagues per-
formed a meta-analysis to investigate this association and 
Table 2. PAI-1 and ACE genotype distribution and allele 
frequencies in patients and controls.
Groups 
 Patient Control p value
PAI 5G/5G 34 (37%) 18 (29.5%)  
 4G/5G 39 (42.4%) 28 (45.9%) 0.43
 4G/4G 19 (20.7%) 15 (24.6%) 0.38
 4G 77 (57%) 58 (43%)  
 5G 107(62.6%) 64 (37.4%) 0.33
ACE I/I 18 (19.6%) 15 (24.6%) 0.23
 I/D 37 (40.2%) 28 (45.9%) 0.25
 D/D 37 (40.2%) 18 (29.5%)  
 I 73 (55.7%) 58 (44.3%)  
 D 111 (64.55%) 61 (35.5%) 0.12
PAI: plasminogen activator inhibitor; ACE: angiotensin-converting en-
zyme; I: insertion; D: deletion.
Table 3. All condition of ACE and PAI combination for CAD 
development.
OR (95% CI) p value
PAI 0.94
 5G/5G 1  
 4G/5G 1.24 (0.28–5.53) 0.77
 4G/4G 1.40 (0.14–13.57) 0.77
ACE 0.11
 I/I 1  
 I/D 1.18 (0.29–4.81) 0.81
 D/D 0.20 (0.03–1.30) 0.09
ACE * PAI 0.37
 I/D * 4G/5G 0.76 (0.12–4.86) 0.77
 I/D * 4G/4G 0.47 (0.03–6.61) 0.57
 D/D * 4G/5G 3.00 (0.31–29.05) 0.34
 D/D * 4G/4G 5.00 (0.28–89.38) 0.27
PAI: plasminogen activator inhibitor; ACE: angiotensin-converting en-
zyme; CAD: coronary artery disease; I: insertion; D: deletion; OR: odds 
ratio; CI: confidence interval.
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showed that PAI-1 4G/5G is an independent genetic risk 
factor for CAD.
To our knowledge, these studies have never been car-
ried out in the Iranian population, more specifically the 
association of the ACE I/D and PAI-1 4G/5G polymor-
phisms and their combination with CAD.
Additionally, there are a few studies that suggest the 
interaction between these two polymorphisms on CAD. In 
2006, Loew and colleagues conducted a cohort study34 on 
907 patients with coronary heart disease to examine the 
association of ACE and PAI-1, and their combination with 
early onset coronary heart disease. This study divided 
patients into two groups: ≤55 and over 55 years, and con-
cluded that no increased risk was observed for each iso-
lated allele. On the contrary, the 4G/4G homozygosity 
combined with the D/D genotype and the adjusted OR 
from confounding factors trebled the risk for early onset of 
coronary heart disease. However, in our current study we 
did not find any elevated risk for CAD in association with 
either PAI-1 or ACE polymorphisms singly or in combina-
tion according to crude and adjusted OR. The control 
group, however, did not undergo any invasive or non-
invasive method to recognize their arterial abnormalities, 
which could be a limitation of this study.
Considering the divergent results from different stud-
ies worldwide, even some meta-analysis on determining 
the impact of the PAI-1 4G/5G and ACE I/D polymor-
phisms on coronary heart disease, it would seem that the 
dependence of these two polymorphisms on race and 
location is significant. Therefore, it is difficult to obtain a 
certain conclusion and generalize it to a universal popu-
lation. It would be more appropriate to use local data-
bases to plan preventive or screening measures on 
cardiovascular disease.
According to our current study and most investigations 
on CAD risk factors to date, conventional and environ-
mental risk factors such as hypertension, diabetes, hyper-
lipidemia and smoking, embodied in lifestyle, are the most 
prominent in CAD development. This is in contrast to 
genetic risk factors, for which their contribution remain 
controversial.
Moreover, further studies should be carried out to assess 
interactions between genes and environment, with a pre-
cise selection of homogenous cases and controls to deter-
mine this association definitely.
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